Featuring perspectives from Ms Ilene Galinsky, Dr Michael J Mauro, Dr Neil P Shah and Dr Sara M Tinsley-Vance, including the following topics:

• Introduction: Chronic Myeloid Leukemia (CML) as a Model for Targeted Treatment (0:00)
• Biology of CML; Role of First- and Second-Generation Tyrosine Kinase Inhibitors (TKIs) as Initial Treatment for Chronic-Phase (CP) CML (12:37)
• Role of Asciminib for Newly Diagnosed CP-CML (47:46)
• Feasibility of TKI Discontinuation for Patients with Sustained Response to Treatment (1:14:06)
• Management of CP-CML After Failure of Initial Therapy (1:23:04)

NCPD information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Andrew J Armstrong, Dr Himisha Beltran, Dr Rana R McKay and Dr Fred Saad, moderated by Dr McKay, including the following topics:

• Introduction (0:00)
• Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Saad (2:12)
• Current Treatment for Metastatic HSPC — Dr Armstrong (26:12)
• Role of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (49:31)
• Current and Future Use of Radiopharmaceuticals for mCRPC — Dr McKay (1:12:51)
• Promising Novel Agents and Strategies Under Investigation for the Management of Prostate Cancer — Dr Beltran (1:36:11)

CME information and select publications

Featuring an interview with Dr Patrick Y Wen, including the following topics:

• Glioma classification (0:00)
• Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50)
• Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55)
• Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46)
• Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30)
• Current and emergent strategies for the management of glioblastoma (31:27)
• Optimizing patient care and quality of life (46:24)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Patrick Y Wen, including the following topics:

• Classification and pathologic diagnosis of gliomas (0:00)
• Role of IDH inhibitors in the management of low-grade gliomas (6:37)
• Ongoing trials and remaining questions in the management of IDH-mutant gliomas (19:53)

CME information and select publications

Featuring perspectives from Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi A Jänne, Dr Suresh S Ramalingam, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics:

• Introduction (0:00)
• Evolving First-Line Treatment for Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Dr Yu (1:47)
• EGFR-Targeted Approaches for Relapsed EGFR-Mutant NSCLC; Strategies to Facilitate Delivery of Recently Approved Agents — Dr Sabari (23:48)
• Potential Utility of TROP2-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Ramalingam (45:16)
• Contemporary Care for Patients with Nonmetastatic EGFR-Mutant NSCLC — Dr Goldman (1:03:56)
• Current and Future Management of EGFR Exon 20 Mutation-Positive NSCLC — Prof Girard (1:24:40)
• Emerging Role of HER3-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Jänne (1:43:46)

CME information and select publications

Featuring perspectives from Dr Geoffrey Y Ku and Dr Zev Wainberg, including the following topics:

• Introduction: ASCO Preview (0:00)
• HER2-Positive Gastroesophageal Cancers (19:03)
• Immunotherapy in HER2-Negative Advanced Gastroesophageal Cancers (36:11)
• Immunotherapy in Microsatellite Instability-High Gastroesophageal Cancers (44:04)
• CLDN18.2-Positive Advanced Gastroesophageal Cancers (51:30)

CME information and select publications

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos and Dr Robert Z Orlowski, including the following topics:

• Introduction: ASCO 2025 Preview (0:00)
• Anti-CD38 Antibodies (10:12)
• Belantamab Mafodotin (29:45)
• CAR T-Cell Therapy (40:57)
• Bispecific Antibodies (47:33)
• Other Novel Agents (56:46)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) — Meletios-Athanasios (Thanos) C Dimopoulos, MD

CME information and select publications